Across TCGA pan-cancer cohorts, FAM111B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM111B data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FAM111B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM111B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and BLCA are the cancer types where FAM111B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	III,IV	0.092	0.649	<.001	24	view →
UCEC	DFS	Median	All	0.940	0.615	.005	14	view →
BLCA	OS	Median	III,IV	0.237	0.688	<.001	12	view →
SARC	DFS	Median	All	0.037	0.632	<.001	6	view →
COAD	DFS	Median	All	0.193	0.697	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: FAM111B tumor-vs-normal RNA expression · all FAM111B data types